<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00497614</url>
  </required_header>
  <id_info>
    <org_study_id>AOHP05-DM/PETRA</org_study_id>
    <nct_id>NCT00497614</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography in Rheumatoid Arthritis With Adalimumab (PETRA)</brief_title>
  <acronym>PETRA</acronym>
  <official_title>18F-FDG Positron Emission Tomography to Study the Response to Adalimumab in Rheumatoid Arthritis. A Monocentric Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Biologics are routinely used for the treatment of rheumatoid arthritis (RA). Adalimumab is a
      human monoclonal antibody that inhibit the Tumor Necrosis Factor alpha (TNF-alpha).
      Identification of RA patients who respond to biologics is a challenging goal to avoid
      unnecessarily, costly and potentially harmful treatment.

      The aim of the study is to address if 18 F FDG is a valuable biomarker for the assessment of
      the clinical response in RA with TNF-alpha blocking agent. Eight patients fulfilling the ACR
      (American College of Rheumatology) criteria will by enrolled. Patient will receive adalimumab
      according to the current guidelines i.e. 40mg /14 days sub cutaneously. The decision will
      stand on a high activity of the disease defined by the DAS 28 (Disease Activity Score) above
      5.1. Positron emission tomography will be performed before, 2 and 12 weeks after the begin of
      the treatment. The response to adalimumab will by assessed by the SUV (standard Unit value)
      measured on the inflammatory joints of hands, wrist, ankle, feet and knees and compared to
      measurement of clinical (total swollen and tender joints count) echographic (synovium
      thickness and power doppler) and chemical biomarkers (erythrocyte sedimentation rate, C
      reactive protein).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>There is no primary outcome measure specified for this study.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>There are no secondary outcome measures specified for this study.</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>No arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>adalimumab</intervention_name>
    <arm_group_label>No arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Patients with active Rheumatoid arthritis PR définie selon les
        critères ACR (1987) (annexe 7) [18], Activité importante de la maladie (DAS 28 &gt; 5,1)
        (annexe 5) [7], Indication d'un traitement par adalimumab (en accord avec l'A.M.M.), Homme
        ou femme dont l'âge est supérieur ou égal à 18 ans, Acceptant de participer à l'étude et
        ayant donné son consentement éclairé, Affiliés ou bénéficiaire d'un régime de sécurité
        sociale.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Denis Mulleman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 4, 2007</study_first_submitted>
  <study_first_submitted_qc>July 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 6, 2007</study_first_posted>
  <last_update_submitted>December 4, 2008</last_update_submitted>
  <last_update_submitted_qc>December 4, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2008</last_update_posted>
  <responsible_party>
    <name_title>University Hospital Tours</name_title>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>Positron emission tomodensitometry</keyword>
  <keyword>Tumor necrosis factor alpha inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

